Piyush K. Agarwal, M.D.
Urologic Oncology Branch
Building 10 - Hatfield CRC, Room 2-5952
Bethesda, MD 20892-1210
Dr. Agarwal is interested in targeted therapy for bladder cancer. One of his current projects is molecular targeted photoimmunotherapy in bladder cancer targeting EGFR, FGFR3, and other mutated and/or over-expressed surface receptors in urothelial cancer. This is in collaboration with Hisataka Kobayashi, M.D., Ph.D., and Peter L. Choyke, M.D. F.A.C.R. (Molecular Imaging Program). In addition, he is conducting a randomized phase II clinical trial for patients with high-grade bladder cancer who have failed at least 1 course of Baccillus Calmette-Guerin (BCG) that is looking at the efficacy of a vaccine combined with BCG. This study is in collaboration with James L. Gulley, M.D., Ph.D. (Genitourinary Malignancies Branch) and Jeffrey Schlom, Ph.D. (Laboratory of Tumor Immunology and Biology).
Rayn KN, Hale GR, Grave GP, Agarwal PK. New therapies in nonmuscle invasive bladder cancer treatment. Indian J Urol. 2018;34(1):11-19.
Railkar R, Krane LS, Li QQ, Sanford T, Siddiqui MR, Haines D, Vourganti S, Brancato SJ, Choyke PL, Kobayashi H, Agarwal PK. Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer. Mol Cancer Ther. 2017;16(10):2201-2214.
Siddiqui MR, Grant C, Sanford T, Agarwal PK. Current clinical trials in non-muscle invasive bladder cancer. Urol Oncol. 2017;35(8):516-527.
Li QQ, Hao JJ, Zhang Z, Krane LS, Hammerich KH, Sanford T, Trepel JB, Neckers L, Agarwal PK. Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics. Sci Rep. 2017;7(1):201.
Park JC, Citrin DE, Agarwal PK, Apolo AB. Multimodal management of muscle-invasive bladder cancer. Curr Probl Cancer. 2014;38(3):80-108.
Related Scientific Focus Areas
Genetics and Genomics
Molecular Biology and Biochemistry
This page was last updated on April 30th, 2019